Kennedy Capital Management LLC bought a new position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 15,466 shares of the company’s stock, valued at approximately $101,000.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its holdings in Terns Pharmaceuticals by 12.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 20,694 shares of the company’s stock worth $136,000 after acquiring an additional 2,261 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Terns Pharmaceuticals by 66.3% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,889 shares of the company’s stock valued at $78,000 after buying an additional 4,742 shares during the period. AJOVista LLC acquired a new stake in shares of Terns Pharmaceuticals during the fourth quarter worth $58,000. Simplicity Solutions LLC bought a new stake in Terns Pharmaceuticals in the 4th quarter valued at $68,000. Finally, Bleakley Financial Group LLC bought a new position in Terns Pharmaceuticals during the 4th quarter worth about $68,000. 98.26% of the stock is owned by institutional investors.
Terns Pharmaceuticals Price Performance
Terns Pharmaceuticals stock opened at $7.77 on Friday. Terns Pharmaceuticals, Inc. has a twelve month low of $3.26 and a twelve month high of $10.03. The company’s 50-day moving average price is $7.55 and its two-hundred day moving average price is $6.61.
Wall Street Analyst Weigh In
A number of research analysts recently issued reports on the company. JMP Securities reiterated a “market outperform” rating and set a $15.00 price objective on shares of Terns Pharmaceuticals in a report on Tuesday, April 30th. HC Wainwright reiterated a “neutral” rating and issued a $5.50 price target on shares of Terns Pharmaceuticals in a research note on Tuesday, May 14th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Terns Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $14.50.
Get Our Latest Analysis on Terns Pharmaceuticals
Insider Transactions at Terns Pharmaceuticals
In other news, Director Carl L. Gordon sold 50,976 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $10.00, for a total value of $509,760.00. Following the completion of the transaction, the director now directly owns 756,258 shares in the company, valued at approximately $7,562,580. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 15.10% of the stock is currently owned by insiders.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.
Further Reading
- Five stocks we like better than Terns Pharmaceuticals
- ESG Stocks, What Investors Should Know
- Take a Bite: This Snack Giant Is a Safe-Haven Stock Worth Buying
- 3 REITs to Buy and Hold for the Long Term
- EA’s New Game Launch Boosts Stock: Is It Time to Buy?
- 3 Stocks to Consider Buying in October
- T-Mobile Stock Poised to Outperform Peers with Stellar Quarter
Want to see what other hedge funds are holding TERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Free Report).
Receive News & Ratings for Terns Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terns Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.